Getinge announces results from SEMPER FI pilot study of intra-aortic balloon pump showing numerical trend toward reduced mortality in patients with extensive myocardial infarction and persistent ischemia

Food and Healthcare Press Releases Monday May 28, 2018 12:29
WAYNE, New Jersey--28 May--PRNewswire/InfoQuest
Study results presented at EuroPCR 2018

Getinge, a leading global provider of innovative medical technology, today announced results from the Survival Improvement in Extensive Myocardial Infarction with PERsistent Ischemia Following IABP Implantation (SEMPER FI) pilot study. The study evaluated the use of an intra-aortic balloon pump (IABP) in patients with extensive myocardial infarction (MI, or heart attack) complicated by persistent ischemia (inadequate blood flow) following primary percutaneous coronary intervention (PCI) – a phenomenon called no-reflow. This small pilot study showed positive trends with IABP in reduction of the primary endpoint (a composite endpoint of mortality, necessity for mechanical support due to hemodynamic deterioration, such as left ventricular assist device [LVAD], and hospital readmission for congestive heart failure at six months). Results were presented yesterday in the hotline coronary interventions oral session at the EuroPCR 2018 Congress in Paris by SEMPER FI co-principal investigator Lokien X. van Nunen, M.D., of Catharina Hospital in Eindhoven, The Netherlands.

Patients with large acute MI and signs of persistent ischemia after successful stenting have a poor prognosis and are likely to develop heart failure in the future. An estimated 30 percent of patients with ST elevated MI (STEMI) continue to have persistent ischemia even after the primary culprit artery is opened.i,ii

"Determining which STEMI patients will benefit from IABP has been difficult because of varying results from retrospective and prospective studies," said Dr. van Nunen. "We are encouraged by the results of the SEMPER FI pilot study, which showed a strong signal that IABP may be beneficial in patients with extensive acute MI who continue to experience ischemia even after stenting. We expect that these results will bear out in a trial adequately powered to demonstrate a statistically significant reduction in the composite endpoint if this trend were to continue."

SEMPER FI Study Design and Results

The prospective, randomized, comparative, single-center SEMPER FI pilot study evaluated the use of IABP in patients with extensive MI complicated by persistent ischemia after PCI. The study included 100 patients ages 18 to 75 years with acute STEMI (characterized by summed ST-segment deviation of ≥15 mmHg) and insufficient ST-segment resolution on an ECG 10 to 30 minutes after PCI (stenting) in the catheterization laboratory. Study participants were randomized to IABP for 12 to 24 hours or no IABP according to guidelines to alleviate persisting ischemia. All were followed up for six months.

Results of this pilot study of 100 patients who presented with large acute MI showed a trend toward decreased mortality, LVAD use and hospital readmission for heart failure within six months with use of IABP. Among the IABP group, 2 percent (one patient) experienced the primary endpoint versus 8 percent (four patients) in the non-IABP group (p=0.16).

"The trend toward a mortality benefit with the use of IABP observed in the SEMPER FI pilot study is encouraging because the study was well controlled and did not allow crossover from the conventionally-treated group to IABP, which could have confounded the results," said Dr. Claudius Diez, Chief Medical Officer, Acute Care Therapies, Getinge. "This pilot study is a testament to Getinge's commitment to support clinical research to increase the body of knowledge for our life-saving therapies."

About IABP Therapy

Based on extensive literature supporting the hemodynamic effects and safety and effectiveness of intra-aortic balloon counterpulsation (IABC), the U.S. Food and Drug Administration (FDA) has cleared balloon pumps for use in patients with acute coronary syndrome, patients undergoing cardiac and non-cardiac surgery, and patients experiencing complications of heart failure of both ischemic and non-ischemic etiologies.iii The FDA clearance for these indications was based on results from a comprehensive literature review of IABC devices, which demonstrated low overall rates of complications despite the fact that patients in whom an IAB was implanted had more severe comorbidities and underlying illnesses than patients without a device. Additionally, the literature shows a trend toward fewer device-related complications over time, as balloon catheter sizes have decreased and procedural techniques have improved in recent years.

About Getinge

Getinge is a global provider of innovative solutions for operating rooms, intensive care units, sterilization departments and for life science companies and institutions. Based on our first-hand experience and close partnerships with clinical experts, healthcare professionals and medtech specialists, we are improving the every-day life for people, today and tomorrow.

i Rezkalla SH, Dharmashankar KC, Abdalrahman IB, Kloner RA. No-reflow phenomenon following percutaneous coronary intervention for acute myocardial infarction: incidence, outcome, and effect of pharmacologic therapy. J Interven Cardiol. 2010;23:429-436.

ii van Nunen LX, van't Veer M, Schampaert S, et al. Intra-aortic balloon counterpulsation in acute myocardial infarction: old and emerging indications. Neth Heart J. 2013;21:554-560.
iii FDA Executive Summary https://www.federalregister.gov/documents/2013/12/30/2013-31218/cardiovascular-devices-reclassification-of-intra-aortic-balloon-and-control-systems-for-acute .
Logo - https://mma.prnewswire.com/media/322743/Getinge___Logo.jpg

Latest Press Release

Venus Medtech Enters North American Market

- First Clinical Implantation of Transcatheter Pulmonary Valve VenusP-Valve in North America was Successfully Performed in Vancouver, Canada On June 12, 2018, St Paul 's Hospital in Vancouver, Canada successfully completed two cases of VenusP-Valve...

What You Think About Getting Old Impacts Your Health, Quality of Life According to New Orb Media Reporting

New Orb Media Inc. reporting and data analysis [ https://www.orbmedia.org/agewell ] shows a strong connection between how we view old age, how well we age and the effects seen across world cultures. Individuals with a positive attitude towards old age...

Johnson Johnson Announces Acceptance of Binding Offer From Platinum Equity To Acquire LifeScan, Inc.

Johnson & Johnson (NYSE: JNJ) today announced that it has accepted the binding offer from Platinum Equity, previously announced on March 16, 2018, to acquire its LifeScan business for approximately $2.1 billion. LifeScan, Inc. is a world leader in...

KTC in association with Bangkok Hospital give a talk on Minimally Invasive Surgery and offer a package of Ovarian and Uterine Cancer Screening.

"KTC" or Krungthai Card Public Company Limited by Ms. Sireerat Corvanich, Vice President - Credit Card Business, sees the importance of health care for women especially with pelvic examination, therefore in association with Women Health Center of Bangkok...

Joint Commission International Appoints New Leadership in Key Strategic Region

Joint Commission International (JCI) is pleased to announce John Yoon, MBA , as JCI's managing director of the Asia-Pacific Region. In this role, he is responsible for developing relationships between JCI and health care organizations, governments,...

Related Topics